#1 - Tim Cash - Senescent Cells: What Are They & Why/How Senolytx Is Trying To Fix Them

Today's episode is an interview with Tim Cash, Chief Science
Officer of Senolytx Therapeutics, one of the six daughter
companies of David Sinclair's Life BioSciences.

In this episode Tim helps me to understand exactly why senescent
cells, and the damage they cause to the human body is such an
important issue we, as humans, need to fix. If you're interested
in learning why and how the human body ages, you're going to love
this episode.

We go over the different methods and theories behind fixing
senescent cells:
senolytics, senomorphics, and utilizing the immune system to get
rid of them naturally, as well as touch on how Senolytx is
navigating the regulatory hurdles by focusing on Fibrosis
initially, as their main target, with the broader goal of
targeting aging as a whole as they progress through clinical
trials.

We also go into some of the promising results Senolytx is seeing
with their therapies, and Tim enlightens me on some of the most
exciting things happening in BioTech right now, and where he
see's things in the next 5, 10, and 15 years.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by
following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited
about, connect with me on Angel List at Angel.co/jamesruhle